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Circulating extracellular RNAs (exRNAs) have the potential to serve
as biomarkers for a wide range of medical conditions. However,
limitations in existing exRNA isolation methods and a lack of
knowledge on parameters affecting exRNA variability in human
samples may hinder their successful discovery and clinical imple-
mentation. Using combinations of denaturants, reducing agents,
proteolysis, and revised organic extraction, we developed an auto-
mated, high-throughput approach for recovery of exRNAs and
exDNA from the same biofluid sample. We applied this method to
characterize exRNAs from 312 plasma and serum samples collected
from 13 healthy volunteers at 12 time points over a 2-month period.
Small RNA cDNA library sequencing identified nearly twofold in-
creased epithelial-, muscle-, and neuroendocrine-cell–specific miR-
NAs in females, while fasting and hormonal cycle showed little
effect. External standardization helped to detect quantitative differ-
ences in erythrocyte and platelet-specific miRNA contributions and
in miRNA concentrations between biofluids. It also helped to iden-
tify a study participant with a unique exRNA phenotype featuring a
miRNA signature of up to 20-fold elevated endocrine-cell–specific
miRNAs and twofold elevated total miRNA concentrations stable
for over 1 year. Collectively, these results demonstrate an efficient
and quantitative method to discern exRNA phenotypes and suggest
that plasma and serum RNA profiles are stable over months and can
be routinely monitored in long-term clinical studies.
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The presence of extracellular RNA (exRNA) and exDNA incirculation is typically considered a consequence of cellular
turnover or formation of microvesicles from blood cells, plate-
lets, and other phagocytic and secretory cells (1) residing in tis-
sues such as liver (2), placenta (3), endocrine organs (4, 5), or
tumors (6), especially under conditions of tissue injury. While the
earliest observations date back almost five decades (7–10), sys-
tematic study of extracellular nucleic acids became increasingly
prominent with the introduction of deep-sequencing technolo-
gies (11). Protected by vesicle enclosure and/or associated RNA-
and DNA-binding proteins, extracellular nucleic acids persist in
cell-free environments despite the presence of secreted and
highly active nucleases (12–14). Considering the distinct cellular
origins of cell-free nucleic acids, variations in its extracellular
concentration and composition may reflect unique metabolic
states and disease processes, and determining their sequence
composition and abundance has been considered valuable for
the discovery of new biomarkers (1, 2, 4, 5, 15–20). In pregnant
women, fetal exDNA released from shedding vesicles of the
placental syncytiotrophoblast cells contribute 10–50% of total
exDNA in maternal circulation, and polymorphic variation spe-
cific to the fetus can reveal chromosomal aberrations (21, 22).
Progress in the exRNA field has been hampered by an inability
to efficiently and reproducibly recover small quantities of cell-
free nucleic acids present in biofluids, nucleic acid size biases
intrinsic to existing isolation methods, and rapid degradation of
exRNAs by nucleases ubiquitously found in biofluids (23–26)
during or following isolation. Varying yield and quality encoun-
tered during exRNA isolation prompted us to modify nucleic
acid isolation protocols until they became suitable for applica-
tion to cell-free serum and plasma (27, 28) to recover nanogram
quantities typically present in 0.5-mL-sized clinical samples at
high reproducibility and purity required for enzymatic cDNA
library preparation and Illumina deep sequencing.
Significance
Nucleic acids mediate storage and expression of genetic in-
formation. Extracellular DNA (exDNA) and exRNA are traces of
nucleic acids released from cells into the extracellular environ-
ment. Their use as disease biomarkers has been limited by
technical challenges in their isolation caused by abundant RNA-
and DNA-degrading enzymes in biofluids. Using isolation pro-
tocols developed especially for biofluids, we generated plasma
and serum exRNA reference profiles from 13 healthy volunteers
over time and determined the effect of critical clinical parameters
such as gender and fasting. Surprisingly, we encountered one
participant with dramatically increased endocrine-origin exRNA
contributions stable over 1 year and detectable in all of his
samples, thereby demonstrating the robustness of this approach
and the clinical potential of circulating RNAs as biomarkers.
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To generate reference data of healthy individuals for future
biomarker studies, we applied this protocol to determine the
extracellular small RNA composition of 312 serum and plasma
samples collected over a 2-mo period from 13 healthy volunteers.
In the case of one individual with a unique and strongly deviating
exRNA signature, an additional time point 1 y later was col-
lected. The sampling intervals and timescale of this study extend
beyond existing studies and enable detailed examination of
exRNA variation across primary clinical variables such as male
vs. female, fasting vs. nonfasting morning and afternoon, time
and individual variability, critical for advancement of exRNA
composition analysis in biomarker discovery, which has been
limited by a lack of knowledge concerning the influence of these
basic factors.
Results
Development of an Extracellular Nucleic Acid Isolation Method
Suitable for Automation. Isolating nucleic acids from cells or
biofluids is challenging due to omnipresent nucleases involved in
nucleic acid turnover, while physicochemical parameters during
purification also strongly impact their recovery. To monitor
nucleic acid integrity, partitioning, and recovery during isolation,
tracer mixes of 5′-32P–labeled single-stranded 19- to 45-nt RNAs
and a 31-nt ssDNA, 5-32P–labeled dsDNA of 24–148 bp, and an
internally labeled 500-nt ssRNA in vitro transcript were spiked in
with the denaturant or extracting agent before the biofluid was
first contacted. This assay enabled us to rectify limitations in
commercial extraction-based RNA isolation and column purifi-
cation approaches, in particular carryover of nucleases or de-
naturants and recovery and separation of exRNA and exDNA
(SI Text: Method Optimization of exRNA and exDNA Isolation and
Fig. S1). The resulting protocol consists of (i) hot sample de-
naturation and proteolytic digestion, (ii) interphase-deprived
organic extraction of digested proteins and DNA while keep-
ing RNA in the aqueous phase, (iii) reextraction of DNA from
the organic phase, and (iv) individual column purifications of
each nucleic acid type using silica matrix columns and vacuum
manifolds or centrifugation (Fig. 1 A and B) in small volumes
free of residual denaturants and other inhibitors of downstream
enzymatic processing steps.
EDTA Plasma and Serum exRNA Isolation and Small RNA cDNA Library
Preparation. Platelet-depleted EDTA plasma and serum samples
were collected from seven male and six female healthy adults
at 12 time points on 4 d evenly spaced over 2 mo (Table S1).
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Fig. 1. exRNA isolation from serum and plasma. (A) Schematic overview of extracellular RNA and DNA isolation procedure detailing addition of calibrator or
radiolabeled DNA and RNA size markers. (B) Examples of RNA and DNA isolations from plasma and serum samples visualized by phosphorimaging of 32P-
labeled spike-in DNA and RNA tracers. Less than 0.1 pmol of labeled tracer nucleic acids (input lane) were added with the denaturant to individual 450-μL
biofluid samples at the first step of the procedure. (C) Average composite read length distributions of 5′P/3′OH-containing exRNAs in platelet-depleted EDTA
plasma and serum samples. (D) Individual miRNA concentration ranges in EDTA plasma and serum. miRNA concentrations were calculated using read
abundance data of Set1 calibrators added with the denaturant at the beginning of the RNA isolation. Boxplots show first to third interquartile ranges and
their medians for plasma (black diamonds) and serum samples (red squares) of all 13 study participants.

















intake) states: AM fasting, 1 h postprandial, and 4 h post-
prandial. Cell-free exRNA was isolated in batches of up to
96 samples from 216 EDTA plasma samples including 60 tech-
nical replicates of all study participants and 96 serum samples
including 24 replicates of six study participants (Dataset S1).
cDNA libraries were generated by processing 24 samples per
batch using barcoded 3′ adapters, and subjecting each batch to
single-read 50-bp Illumina HiSeq sequencing (29). To monitor
the recovery of exRNAs from each sample and batch, we spiked
the denaturant solution at the start of RNA isolation with a
defined amount of a mixture of 10 synthetic 5′-phosphorylated
nonradioactive 22-nt calibrator RNAs (Set1), which served as an
external standard in subsequent analysis. Before preparation of
the small RNA cDNA libraries, another mixture of 10 synthetic
5′-phosphorylated nonradioactive 22-nt calibrator RNAs (Set2)
was added to the sample. All calibrator RNA sequences were
distinct from human genome assembly 19 (hg19) genome or
transcriptome by at least two mismatches (30).
We obtained an average of 169 million reads per cDNA library
batch. Of these reads, an average of 53% comprised sequence
inserts within the targeted size range, while 28% were insertless
or comprised repeated adapter sequences. Following barcode
extraction, the average serum and plasma sample-derived cDNA
library yielded 4.5 and 3.2 million reads, respectively (summa-
rized in Table 1; detailed metadata and read statistics in Dataset
S1). Sequence reads were mapped to annotated reference RNAs
(31). Of these reads, 3.0 and 2.3 million, respectively, mapped to
hg19 including the RNA annotation classes miRNAs, rRNAs,
tRNAs, small cytoplasmic RNAs (scRNAs), and mRNAs. For
comparison across samples, read counts were normalized and
reported as relative read frequencies (31).
The relative read frequencies for calibrators varied between
0.1% and 7% per sample, with average read frequencies of 0.7%
for Set1 and 1.2% for Set2. Based on relative read frequency for
Set1 compared with Set2, an exRNA recovery efficiency of
∼42% was achieved. Rare instances of less than 2% recovery
were traced to obstructed microtiter plate wells (production er-
rors) during plate-based nucleic acid purification.
ExRNA Classes and Their Size Distribution in Serum and Plasma of
Healthy Volunteers. The overall composition of plasma and se-
rum by class of RNA was distinct. In plasma, miRNA was cap-
tured with a median of 80.9% of the sample-derived nontechnical
reads (total reads – technical reads), with less than 4% each of
rRNA, scRNA, or mRNA, and 0.4% of tRNA (Table 1). In se-
rum, the miRNA content was lower with a median of 54.5%, while
rRNA, scRNA, and tRNA were each near 10%. The relative
contribution of reads annotated as mRNA was similar in plasma
and serum at a median close to 4%. The read size distribution of
each class of RNA was similar in plasma and serum and peaked at
22 nt for miRNAs, 30 nt for tRNAs, and 32 nt for scRNA, while
mRNA, rRNA, and nonannotated reads were more broadly dis-
tributed between 17 and 40 nt (Fig. 1C and Fig. S2).
The read depth for sample-derived nontechnical reads was
≥100,000 and ≥2,000,000 in 96.2% and 39.7% of all samples,
respectively. Thirteen samples with less than 100,000 sample
reads were excluded from further analysis.
Extracellular miRNA Content and Composition of Plasma and Serum.
Concentrations of extracellular miRNA in biofluids were calcu-
lated based on the ratios of miRNA read to calibrator-Set1 read
counts, the molar amount of Set1 spike, and the sample volume.
Total miRNA concentration medians in repeat samples of study
subjects (excluding subject P12; see below) ranged from 4.4 to
10.9 pM for plasma and 3.8 to 7.7 pM for serum (Fig. 1D).
Relative read frequencies for miRNA and calibrator were
reported in separate heatmaps subjected to unsupervised clus-
tering (Fig. 2). Considering samples with ≥2,000,000 reads, cal-
ibrator profiles did not cluster by batch, subject, or type of
biofluid (Fig. 2A); however, subsets of samples clustered by 3′
adapter reflecting small, yet noticeable sequence biases of en-
zymatic adapter ligation to a small subset of input RNA se-
quences (32). Similar results were obtained when calibrators of
all samples with ≥100,000 sample reads were included (Fig.
S3A), although, in some samples with less than 2,000,000 total
reads, calibrator clustering was driven by the absence of infre-
quent sequences.
For unsupervised clustering of miRNA profiles, we selected
the union of miRNAs represented within the top 90% of cu-
mulative miRNA-annotated reads of any sample. Clustering
separated samples according to biofluid type but not by indi-
vidual or other metadata (Fig. 2B and Fig. S3B). Surprisingly, all
samples of P12 characterized by elevated extracellular RNA
content clustered distinctly from other study subjects, although
they still showed some separation by biofluid type. Batch effects
were unnoticeable, although some samples subclustered by 3′
adapter within each of the biofluid branches.
For differential expression analyses (DEAs), miRNA size
factor estimation (SFE) for count normalization typically con-
sidered all miRNA counts in a sample unless stated otherwise;
considering miRNAs with base mean counts of at least 10, DEA
of serum (n = 84) vs. plasma (n = 194) samples excluding
P12 identified 98 and 15 miRNAs, which showed absolute log2
fold changes (lfcs) ≥1 to <2 and ≥2, respectively (Padj ≤ 0.05,
Fig. 3A and Dataset S4, A). The abundant red blood cell (RBC)
enriched miR-144, 451, and 486 (Fig. 3C) (33) were prevalent in
platelet-depleted EDTA plasma (lfc ≈ −2) used in this study. In
contrast, the platelet (PLT) and peripheral blood mononuclear
Table 1. Summary table of sequencing reads and annotated read statistics
Calibrators RNA category, %
Biofluid Total Set 1 Set 2 Sample miRNA rRNA tRNA scRNA Other cRNA mRNA non-hg19 Technical
Serum, n = 96 Average 4,568,021 12,090 18,909 2,984,332 53.4 8.5 6.6 9.7 1.6 5.2 14.8 1,552,689
Median 2,190,478 6,384 10,202 1,473,132 54.5 7.8 5.6 7.9 1.6 4.6 12.3 602,986
Min 91,780 214 723 51,795 17.7 1.0 0.3 2.1 0.7 0.8 2.5 25,798
Max 31,993,329 124,488 193,438 23,141,839 81.6 19.8 20.2 39.1 2.4 21.8 62.2 12,056,077
Plasma, n = 216 Average 3,242,576 7,784 11,448 2,255,037 77.8 2.8 0.6 3.1 1.2 4.7 9.8 968,308
Median 2,041,473 5,883 8,524 1,411,639 80.9 2.5 0.4 2.5 0.9 3.7 7.0 429,009
Min 21,955 47 143 13,300 26.6 0.7 0.2 0.2 0.3 0.8 1.1 2,011
Max 19,671,378 56,088 81,127 15,970,087 94.4 9.2 6.5 17.5 6.6 29.5 58.7 15,767,594
Listed are median, minimal (min), and maximal (max) mapped reads on a per-sample basis for plasma and serum. The technical read category includes
reads mapped against plasmid and genome sequences of the expression system used in production of RNA ligase 1 and 2, which are used for the 5′- and
3′-adapter ligations in cDNA library preparation, as well as marker sequences and reaction side products. Individual sample read reports are detailed in
Dataset S1.














































































































































































































Fig. 2. Unsupervised clustering of miRNAs from human biofluid samples reveal distinct miRNA signatures for serum and plasma and segregate subject
P12 from otherwise indistinguishable study participants. For each sample, individual calibrator and miRNA read frequencies from Dataset S2 are log2-
transformed and color-coded. Study subject metadata and library preparation details are color-coded and indicated as annotation. This figure features
samples with ≥2,000,000 hg19-mapped reads; an equivalent panel of samples with a lower cutoff ≥100,000 reads is included as Fig. S3. (A) The calibrator
heatmap reports unsupervised clustering of two sets of 10 synthetic 22-nt 5′P/3′OH-containing oligoribonucleotides spiked into samples at the beginning of
RNA isolation (Set1) and before small RNA cDNA library preparation (Set2). (B) The miRNA heatmap is based on the union of the top 90% of miRNAs present
in any sample. Sample order (columns) and miRNA arrangement (rows) were determined by hierarchical clustering. All biofluid samples from study subject
P12 (green) clustered together yet were different from the rest of samples.








































































































































































































































































Fig. 3. Differences in miRNA abundance based on type of biofluid, individual P12, gender, female hormonal cycle, and prandial state. MA plots are based on
merged miRNA read counts from Dataset S3 and tabulated values describing lfc values, and their significance can be found in Dataset S4. Significant dif-
ferences in abundance are indicated by red dots for Padj < 0.05. Blood-based miRNAs are labeled in red (RBCs) and green (platelets/PBMCs). Select examples of
additional miRNAs discussed in the text are labeled black when their abundance variance is greater than fourfold (lfcs ≤ −2 or ≥2), while smaller magnitudes
are shown in gray. A count of 10 normalized reads, which has been chosen as a lower threshold for data analyses to eliminate noise, is indicated by a dashed
vertical line. Count normalization in this analysis considers all miRNA sample reads, unless stated otherwise. (A and B) Serum vs. plasma, excluding individual
P12, considering all miRNA reads (A) or utilizing miR-451 and 144 as standards (B) for SFE/miRNA read count normalization. (C) Unsupervised clustering
separating miRNA signatures of biofluid representatives and those of RBC, PBMC, and platelets; only a few abundant miRNAs show enrichment in some of
these major cellular or cell-derived blood constituents (red, green: higher relative abundance in RBC and platelets/PBMCs, respectively). (D–F) Study subject
P12 vs. other male study participants, plasma (D and F) and serum (E). In F, we used Set1 calibrator reads for SFE/read count normalization. (G) Effect of
gender, comparing female vs. male (plasma). For the corresponding serum comparison, see Fig. S4A. (H) Effect of menstrual cycle, comparing follicular vs.
luteal state, in plasma. For the corresponding serum comparisons, see Fig. S4E. (I) Effect of fasting: preprandial vs. 4-h postprandial state, in plasma. For the
1-h preprandial vs. postprandial state comparison, see Fig. S4F.
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cell (PBMC)-enriched miR-223 (lfc = 2.7) and 199a-5p (lfc =
1.7) (33) were prevalent in serum. Reevaluation of serum-to-
plasma comparisons ratios utilizing Set1 calibrator reads as ex-
ternal normalization standards confirmed the approximately
threefold reduced abundance of many miRNAs including RBC
miRNAs in serum (Dataset S4, A_Set1), which is likely a con-
sequence of increased exRNA degradation or their adsorption to
the blood clot during coagulation to obtain serum. The resulting
twofold reduction in total individual miRNA concentrations of
serum vs. plasma (Fig. 1D) is likely caused by miRNA release
from PLTs during coagulation (34). Cellular miRNA profiles
from RBC, PBMCs, and PLTs, and 10 representative serum and
plasma samples, excluding study subject P12, subjected to un-
supervised clustering (Fig. 3C) support this interpretation.
Assuming that overall miR-451 und 144 abundances in the
biofluid do not notably change during serum formation and may
be utilized as internal standards for SFE, miRNA contributions
from platelets may increase 20-fold during coagulation com-
pared with platelet-depleted plasma, as suggested by abundance
changes of platelet specific miR-223 (Fig. 3B and Dataset
S4, A_451,144).
Study Subject P12 Shows a Unique Extracellular miRNA Composition
Stable over 1 y. The total miRNA concentrations of subject
P12 corresponded to 19.0 and 18.5 pM for plasma and serum
samples, respectively, and were at least twofold higher compared
with other healthy controls (Fig. 1D). The difference was highly
significant (Padj ≤ 0.0002, Tables S2 and S3), while the other
interindividual miRNA concentration comparisons showed no
significant systematic differences or sporadic significant differ-
ences conserved across biofluid types. Considering an average
read count of at least 10 DESeq2-normalized reads, comparison
of biofluid samples from study subject P12 to other male healthy
volunteers’ differences observed in sera highly correlated with
differences found in plasma samples (RPearson = 0.92 for 166
common lfc pairs with Padj ≤ 0.05 in both comparisons). Totals of
115 and 57 significant abundance differences in plasma with
absolute lfcs ≥1–2 and ≥2, respectively (Fig. 3D and Dataset S4,
B1), were observed, and 93 and 40 in serum (Fig. 3E and Dataset
S4, B2) (Padj ≤ 0.05; n = 12 and 22 for P12; n = 36 and 92 for
other males in serum and plasma, respectively). Negative lfcs
including the most abundant miRNAs in plasma and serum of
subject P12 compared with other males as well as across different
biofluid types invoked substantial changes in abundance, which
were also supported by the doubled miRNA concentrations in
P12 (Fig. 1D); in this situation, default miRNA read normali-
zation for DEA may be compromised, because it assumes min-
imal abundance changes for the majority of miRNAs across all
samples to reliably estimate sample size factors, which are based
on the medians of individual size factors of each miRNA present
in a sample. Reevaluating the DEA of P12 vs. other males uti-
lizing Set1 calibrator counts as external normalization standards
returned the most abundant RBC-derived miRNA lfcs close to
zero and left only few miRNAs with significant negative lfcs (Fig.
3F and Dataset S4, B1_Set1 and B2_Set1), suggesting a similar
miRNA background in P12’s circulation as in the other partici-
pants. This result was confirmed utilizing RBC miR-451 and
144 as internal standards for SFE (Dataset S4, B1_451,144 and
B2_451,144). Consequently, many more miRNA members in-
cluding neuroendocrine miR-375, endothelial miR-141 and 200a-c,
muscle-specific miR-1, and liver-specific miR-122 (33, 35, 36)
now showed greater positive lfcs, indicating an increased con-
tribution from these cell types to miRNAs in the circulation of
P12. miRNA abundance differences of similar magnitude were
observed, when P12 was compared with all other healthy vol-
unteers. A thorough medical, surgical, and social evaluation both
at the time of the initial blood draw and 1 y later, as well as a
complete blood count, blood chemistries, liver function tests, and
an abdominal MRI were normal (Fig. S5 and Table S4) despite
the fact that his signature prevailed (Fig. 2B, samples “P12,
1 y later”).
Sex-Dependent Differences in Serum and Plasma miRNA.Considering
miRNAs with an average abundance ≥10 DESeq2-normalized
reads, comparison of samples of female vs. male healthy volun-
teers showed intermediate correlation between plasma and serum
(RPearson = 0.68 for 15 common lfc pairs with Padj ≤ 0.05 in both
comparisons). Disregarding study participant P12, 15 and
49 miRNAs in women’s plasma (n = 102) and serum (n = 48),
respectively, showed at least 1.5-fold altered abundance relative to
men’s plasma (n = 96) and serum (n = 32) (lfcs ≤ −0.6 or ≥0.6,
Padj < 0.05; Fig. 3G, Fig. S4A, and Dataset S4, C1 and C2). The
maximum miRNA changes in plasma and serum were 2.4- and
4.4-fold, respectively. Among those elevated in women in both
biofluids were epithelial cell-type–enriched cistronically organized
miR-141, 200c, 429, and 200a, 200b, muscle-specific miR-1, and
neuroendocrine-specific miR-375 (33, 35, 36).
To evaluate the extent by which sex-dependent differences are
impacted by personal baseline miRNA contributions of volun-
teers, we performed two approaches using the larger plasma
dataset. We first compared two groups composed of three male
and three female volunteers each (P1, P3, P5, P9, P10, P14 vs.
P2, P4, P6, P7, P11, P13), and observed five miRNAs with at
least 1.5-fold altered abundance (lfcs ≤ −0.6 or ≥0.6; Padj < 0.05;
Fig. S4D and Dataset S4, C5), including some of the 15 sex-
dependent miRNAs observed in plasma above. We also omit-
ted one individual from the male or female groups above and
recalculated abundance differences; in particular, omission of
female P11 reduced the contributions of epithelial cell-type
miRNAs from average 2.0- to average 1.6-fold differences (Padj
values ranging from 1.13E-02 to 1.90E-07; Fig. S4 B and C and
Dataset S4, C3 and C4). These controls indicate that apparent
gender differences are small and influenced by personal miRNA
baseline variation.
Comparison of miRNA abundance by follicular (n = 28) and
luteal (n = 52) state of the female menstrual cycle identified no
significant changes in plasma (Fig. S4E and Dataset S4, D2). In
serum (n = 12, 24 for follicular and luteal state, respectively),
seemingly significant changes (Padj ≤ 0.05) were observed for two
low-abundance passenger miRNAs also referred to as miRNA*
(37), for which, however, the corresponding mature miRNA
showed lesser and not significant lfcs (Fig. 3H and Dataset S4,
D2). We conclude that menstrual cycle states do not affect ex-
tracellular miRNA profiles.
Food Intake Does Not Impact Plasma and Serum miRNA Composition.
Comparison of miRNA abundance between fasted (n = 61, 26)
and postprandial states identified no significant changes 1 h after
food intake (n = 67, 28) in serum and plasma, respectively (Fig.
S4F and Dataset S4, E1 and E2). Four hours after food intake
(n = 66, 30), one seemingly significant change (Padj ≤ 0.05) was
detected in plasma, but not in serum (Fig. 3I and Dataset S4,
E2 and E4). As stated above, the variation was observed for one
low-abundance passenger strand miRNAs, for which, however,
the corresponding much more abundant mature miRNA was
unchanged. We therefore conclude that prandial state does not
affect plasma or serum miRNA profiles.
Discussion
Our exRNA isolation method facilitated automated, high-
throughput sequential recovery of exRNA and exDNA from
biofluids with improved speed, yield, and intactness, overcoming
size biases and limitations caused by low-input nucleic acid
concentrations and high nuclease activities in conventional
TRIzol-based extraction and column-based purification methods.
Revision of extraction conditions enabled doubling of sample

















volumes compared with current commercial RNA extraction
solutions, allowing the processing of up to 450 μL of biofluid in
standard 1-mL deep-well plates compatible with automated liq-
uid handling, as recommended by the latest guidelines for total
exRNA recovery from biofluids (https://exrna.org/resources/
protocols/). Elimination of interphases, a common limitation in
existing extraction methods, which notably affects RNA recovery
and increases processing times, allowed full automation of the
method, enabling processing of hundreds of samples per day using
a standard 96-well liquid handling system. This methodology is
already feasible for detailed and cost-effective characterization of
large sample collections, and in combination with small RNA
cDNA sequencing, it allows screening of large sample collections
for exRNA biomarker discovery. Combining our exRNA isolation
protocol with RT-qPCR assays for validating a limited set of
exRNAs may be a practical and even faster alternative, and
adaptable to routine screening applications in the clinic.
For RNA quantification and quality control throughout the
entire process of sample handling, we introduced two distinctive
sets of 10 22-nt calibrator RNAs each, which do not map against
the human genome. The sum of calibrator-annotated reads and
their defined molar amounts spiked-in during RNA isolation
were utilized to determine miRNA concentrations in biofluids.
Calibrator Set1 allows for determination of miRNA concentra-
tion before RNA isolation, while calibrator Set2, spiked after
RNA isolation, provides information about the RNA recovery
yield. Furthermore, the use of calibrators also proved critical to
the unanticipated discovery of global twofold elevated extracel-
lular miRNA concentration in plasma and serum of study par-
ticipant P12, stable over an observation period of more than 1 y.
Combining absolute miRNA quantification and calibrator-guided
scale factor estimation in DEA helped to overcome normalization
biases caused by differences in global sample composition changes
and allowed to discover and dissect the origins and background
contributions of extracellular miRNAs. Because external stan-
dardization using calibrators appears less prone to changes in
global composition than internal standardization approaches, we
expect it to be beneficial to acquire composition changes more
accurately in samples, which differ considerably in their exRNA
compositions such as different biofluid types.
Biofluid type, serum or plasma, was a biological variable that
impacted the miRNA profile and therefore must be taken into
account when collecting and analyzing extracellular miRNA
profiles. Differences between serum and plasma miRNA com-
position are substantial, and additional platelet contributions
before and after coagulation are significant. Consequently, the
extent of platelet depletion in plasma samples is a critical vari-
able, as well as losses of exRNA by surface adsorption on the
blood clot or additional RNA degradation paired with the re-
lease of platelet-contained RNAs upon coagulation. Platelet-
depleted plasma generated immediately after blood collection
therefore constitutes the preferred sample collection process for
exRNA biomarker discovery.
Gender-associated abundance variations are small and char-
acterized by 1.5- to 2-fold differences in abundance of cistroni-
cally expressed, epithelial cell-specific miR-200a, 200b, 429, and
miR-141, 200c, as well as muscle-specific miR-1. While these
miRNAs show abundance differences, the personal variability is
high, and individually they provide sensitivity and specificity
values of up to 73% (miR-200b) and therefore do not allow to
accurately discern gender. Two other studies (38, 39) reported
similar effect sizes but their gender-discriminating miRNAs
agreed neither with each nor with the miRNAs identified in our
study, indicating that gender differences are small and variation
by individual and experimental noise are of almost similar
magnitude. Other clinical parameters such as fasting and the
menstrual cycle did not measurably affect miRNA profiles and
need not be controlled for.
Considering that the blood-derived background of abundant
miRNAs in the circulation of subject P12 is similar to that of other
individuals, despite his twofold-increased total miRNA concen-
tration in circulation, >130 up-regulated miRNAs may allow
identification of additional contributing tissue sources (Figs. 3 D
and E and 4A). Among them are approximately twofold relative
increases of the prevalent miR-21, abundant in many proliferating
cells, and liver-specific miR-122 and 22. miR-375, specific to neu-
roendocrine cells, such as those present in the pancreas and pitu-
itary gland (33, 35, 36), showed an even greater relative 20-fold
increase compared with all other males. miR-320, which is more
broadly expressed including neuroendocrine cells (35), showed a
relative 6.2-fold increase. Displaying median read frequencies of
about 1% in P12 and less than 0.1% in all individuals, both miR-
375 and 320 were of low abundance, yet their differential expres-
sions were highly significant (Padj < 10
−20), allowing us to discern
this phenotype in virtually every sample originating from subject
P12 (Fig. 4A), and could therefore serve as diagnostic markers
with ≥90% sensitivity and specificity (Fig. 4B).
Despite this remarkably different exRNA phenotype, to date we
have not identified an etiology that accounts for this profile. Further
longitudinal studies of this individual and a larger pool of study
subjects including family members will provide insight into whether
this phenotype predicts a genetic condition and predisposition to
disease or represents a benign variant of cellular RNA metabolism
and/or vesicular sorting and secretion, contributing to RNA release
into biofluids, or exRNA turnover and secretion.
Finally, the discovery of an atypical extracellular miRNA phe-
notype in the course of this study, albeit without thus far identified
clinical implications, indicates that our isolation, processing, and
analyses are sufficiently sensitive and reproducible to capture even
a singular abundance change of lower-prevalence miRNAs, in-
dependent of time, biofluid type, and gender. The implemented
automation and adaptation to routine clinically collected biofluid
volumes will facilitate larger clinical studies and accelerate RNA
biomarker discovery.
Materials and Methods
All materials and methods for optimization of extracellular nucleic acid iso-
lations from biofluids are listed in SI Text: Method Optimization of exRNA and
exDNA Isolation. All oligonucleotide sequences used in exRNA/exDNA iso-
lation and sRNA-derived cDNA library preparation are also listed in this text.
Human Subjects. All clinical investigation has been conducted according to
Declaration of Helsinki principles. All aspects of this study were reviewed and
approved by the institutional review boards at Albert Einstein College of
Medicine (IRB #2013–2248) and The Rockefeller University (under protocol
number TTU0707). Signed informed consent was received from participants
before inclusion in the study.
Plasma and Serum Collection. Thirteen healthy subjects, seven males and six
females, were recruited from Bronx, New York, to participate in this study; their
demographic andadditionalmetadata are listed in Table S1. Inclusion criteriawere
absence of any chronic or active diseases, not using any medications, and having a
normal body mass index (18.5–29.9 kg/m2). Study subjects had to be on normal
day schedules. Female study participants were required to have regular menstrual
cycles of 26–32 d and could not be using any hormonal contraceptives. For each
study subject, blood samples were collected on 4 dwithin a 2-wk interval. On each
collection day, a standard 12-h clinical biochemistry fasting protocol was executed;
the fasting blood sample was collected at 8 AM, a postprandial sample at 9 AM,
and an afternoon sample at 4 PM. Records were kept of the activity of the study
participants including food and drink ingested, physical activity, and sleep/wake
cycles. Menstrual cycle information was recorded for female participants. Con-
sidering that coagulation releases platelet-containing miRNAs and thereby di-
minishes the signal of exRNAs originating from other cell types (16), we collected
and sequenced less serum than plasma samples.
Sample collection was performed over a period of 4 mo, from November
19, 2014, to March 24, 2015. For each blood collection, the first 1 mL of
peripheral blood after venipuncture was collected into a 3-mL plastic
additive-free tube (BD; 366703) and discarded. Then, bloodwas collected into
three 10-mL K2EDTA Vacutainer tubes (BD; 366643) and one 7-mL serum
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tube (BD; 366431). The K2EDTA tubes were immediately inverted 12 times
to mix anticoagulant additive with blood. Blood in the serum tube was kept
at room temperature for 45 min to allow clot formation. To obtain plasma/
serum, blood samples were fractionated by centrifugation at 2,500 × g for
15 min at room temperature in a swinging-bucket centrifuge (Eppendorf;
5810R). Plasma/serum was aspirated into 50- and 15-mL tubes using disposable
transfer pipettes (VWR; 414004-047) and centrifuged again using the same
parameter. The supernatant plasma/serum supernatant was carefully trans-
ferred into new 50- and 15-mL tubes, mixed by inverting three times, and then
aliquoted into 2-mL DNA LoBind tubes (Eppendorf; 0224310210). Samples
were snap-frozen in liquid nitrogen and stored at −80 °C.
Optimized RNA Isolation, cDNA Library Preparation, Deep Sequencing, and
Bioinformatic Analysis. Detailed step-by-step protocols for RNA isolation and
sRNA-derived cDNA library preparation are available in the SI Appendix. Before
processing, all samples were randomized and organized in batches of 24 sam-
ples, and each 450-μL biofluid sample was quickly mixed with 105 μL of 60 °C-
preheated detergent buffer P [30% (wt/vol) SDS, 66 mM Tris·HCl, pH 7.5,
19.8 mM EDTA, 265 mM 2-mercaptoethanol, pH 8.0] containing Set1 calibrators,
a mixture of 10 unique non-hg19–mappable 22-nt 5′P/3′OH RNA spike-ins at a
concentration of 10 pM each, so that the absolute total amount of
Set1 calibrators added to each sample was 20 amol. Denaturation was followed
by addition of 28 μL of proteinase K solution (5.4% glycerol, 3.2 mM CaCl2,
5.4 mM Tris·HCl, pH 8, 2.1 mg/mL proteinase K) and proteolytic digestion for
10 min at 60 °C, then organic extraction with 513 μL of buffer ED2 [37.4 mM
citric acid/sodium citrate, pH 4.3, 0.4% sarcosyl, 1.6 M guanidinium iso-
thiocyanate (GITC) and 80% phenol, 50 mM 2-mercaptoethanol], cooling to
10 °C, and phase separation with 103 μL of chloroform and centrifugation at
3,700 × g for 5 min. Column binding was performed by mixing 650 μL of the
aqueous phase with 1,200 μL of buffer VB2G [98.2% isopropanol, 7.2 mMMgCl2,
2.4 mM CaCl2, 1 M GITC, and 5.0 mM tris(2-carboxyethyl)phosphine (TCEP)]
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Fig. 4. miRNA abundance variability in individual P12 compared with other individuals. (A) Boxplots featuring Set1-calibrator normalized read counts of
select miRNAs, which are either prevalent in plasma (pink) and serum (sage) and show no significant difference (miR-451, 144, 223); or which are tissue
specifically expressed and are significantly more abundant in individual P12 (miR-1, 122, 200a, 375, 320). miRNA abundance was computed using Set1-
normalized count data. (B) Receiver operating characteristic curves based on miRNA 375 and 320 read counts.

















(Zymo Research Corporation), followed by vacuum-applied washes with 970 μL
of solution EWL (18 mM NaCl, 2.7 mMMgCl2, 0.9 mM CaCl2, 0.5% Triton X-100,
360 mM GITC, 5 mM TCEP) twice, 970 μL of 100% ethanol once, and 500 μL of
80% ethanol twice. RNA was eluted in 21 μL of 10 mM Tris·HCl, pH 7.4, by
centrifugation at 3,700 × g for 5 min. If optional DNA extraction was desired,
organic phases from organic extraction were reextracted using 500 μL of buffer
EA3 (35.5 mM citric acid/sodium citrate, pH 4.3, 4 mM GITC), followed by cen-
trifugation, aqueous phase aspiration, binding, washes, and elution from col-
umns as described above for the purification of RNA. Nine microliters of each
eluate, representing ∼50% of the isolated RNA extracted from one 450-μL
biofluid sample, was used for cDNA library generation. Calibrator Set2 was
added to each 9-μL aliquot, using absolute amounts of 1 amol each, so that the
resulting total amount of Set2 calibrators added was 10 amol. Each RNA sample
was individually 3′-adapter ligated. Up to 24 reaction products were then
pooled, size-selected by denaturing 15% PAGE from 19 to 45 nt, 5′-adapter li-
gated, reverse transcribed, PCR amplified, and sequenced in a single Illumina
HiSeq lane. Reads were demultiplexed, mapped against a curated hg19-based
miRNA reference transcriptome, sorted, and tabulated into different RNA cat-
egories (summarized in Table 1, individually listed with complete metadata
annotations in Dataset S1).
Raw sequencing data were processed (Illumina software suite), followed by
read extraction using an in-house RNA-sequencing data analysis platform
(RSDAP) (40) specifying a size range of 16–45 nt and default parameters.
Demultiplexed RNA sequencing data were mapped against our curated hu-
man reference transcriptome to obtain miRNA raw read and read frequency
profiles as well as abundance of fragments of other RNA classes, such as tRNAs,
snRNAs, scRNAs, and rRNAs. Mapped data were used to generate RNA sum-
mary tables, as well as detailed miRNA raw read and read frequency tables,
which were used for DEA and unsupervised clustering, respectively.
Sequencing data reported in this paper have been deposited in NCBI’s Gene
Expression Omnibus (41) and are accessible through GEO Series accession no.
GSE113994. Per-sample fastq files have also been deposited in the Extracellular
RNA Communication Consortium (42) exRNA atlas (43) and are accessible
through accession no. EXRTTUSC1gCrGDHAN.
Data Processing. Reads annotated as calibrator, expression system (plasmid
and Escherichia coli), marker, and adapter were considered as reads of
technical origin or “technical reads”; those remaining were considered as
reads derived from the sample and referred to as “sample reads.” A total of
299 biofluid samples (95.8%) of a total of 312 samples were considered for
data evaluation, and 13 samples with less than 100,000 sample reads were
excluded. Reduced read coverage in these samples appears to be caused by
column obstructions, RNA-ligation biases, low RNAseq efficiency, and com-
binations thereof: five samples were derived of batch 58 and 102 showing
reduced sequencing depths of 110 and 56 million total reads, respectively
(Dataset S1, column V); six samples showed notably reduced RNA isolation
efficiencies (ratio of Set1 and Set2 calibrator counts; Dataset S1, column W
and X); nine samples were barcoded with adapters 6, 11, 13, and 19, which
tend to result in lesser than average read counts in multiplexed setups (29).
Estimation and comparison of miRNA concentrations using Set1 calibrators as external
standards.miRNA concentrations were calculated from the sum of Set1 calibrator
read counts, considering their added molar amounts and volumes of biofluid
samples. miRNA concentrations of study subjects were compared by one-way
ANOVA assuming no matching or pairing, followed by Tukey’s multiple-
comparisons test (44) using GraphPad Prism (version 7.00 for Mac; GraphPad
Software, www.graphpad.com). Only comparisons where the level of difference
was found to be of high significance (Padj < 0.01) were reported.
Calculation of read length distributions. Read length distributions were based on
length-dependent fractional values considering a range of 19–45 nt com-
puted for major exRNA classes (miRNA, tRNA, rRNA, mRNA, ncRNA) using
collapsed exRNA-seq data extracted from RSDAP master tables: (i) For each
RNA class in each sample, individual length distribution fractions were
generated for each length l in the range, by dividing the sum of sequences
featuring the length l by the total number of sequences; in both cases, RNA
class-specific sequences were considered. (ii) For each sample class (serum,
plasma), averaged length distribution profile, fractions, and their SDs were
calculated for each length l of each major exRNA class from individual read
fraction values (see i) of relevant sample within that class. (iii) Composite
sRNA length distribution fractions were calculated for each length l of each
major RNA class of each sample class, by multiplying averaged fractional
values (see ii) with averaged total read fraction values for that combination
of RNA class and sample class, extracted from merged stat summary tables.
Unsupervised hierarchical clustering. Tabulated shared read fractions of merged
miRNAs and calibrators reported by RSDAP (Dataset S2) were used to gen-
erate log2-transformed heatmaps using the heatmap package (Raivo Kolde,
2015; pheatmap: Pretty Heatmaps; R package, version 1.0.8, CRAN.R-project.
org/package=pheatmap). Unsupervised clustering of fractional miRNA
abundance values was performed using the Complete clustering method
and Manhattan clustering distances for both rows (miRNAs) and columns
(samples) considering the combined top 85% most abundant miRNAs across
all samples, unless stated otherwise. Calibrator heatmaps were generated
accordingly by considering fractional calibrator read abundances of all
members in calibrator Set1 and Set2, except that only the sample order was
subjected to clustering while the order of calibrators was kept constant.
Selected metadata (individual, gender, biofluid type, prandial state, female
reproductive cycle, processing batch, and adapter detailed in Fig. 2 and Fig.
S3) were included as metadata annotation where required.
DEAs. For miRNA count data, we used the package DESeq2 (45), which provides
methods to test for differential expression by use of negative binomial gener-
alized linear models. This approach has been used to analyze and quantitate
exRNA abundance differences (46), while also providing statistical significance
with multiple testing corrections of all differences found. Tabulated shared raw
reads of merged miRNAs reported by RSDAP (Dataset S3) at a level of at least
five counts across all samples were used to investigate abundance differences
associated with biofluid (serum vs. plasma), gender (female vs. male), female
reproductive cycle (follicular vs. luteal state), prandial state (postprandial vs.
preprandial state), and individual miRNA profiles. Single case profiles (e.g.,
P12 vs. other male subjects) required a comparison of data from a single indi-
vidual with that from a group of controls, to ascertain whether the patient’s
biofluid miRNA profile can be viewed as significantly different from that of
controls. Various methods have been used in classical statistical inference to deal
with such data, including repeated-measures ANOVA (47). Use of external stan-
dards based on read counts of all 10 oligonucleotides in the Set1 calibrator mixture
for the size factor optimization proved to be critical for the correct description of a
phenotype with a notably deviating exRNA composition. Although this phenotype
has only been observed in one study participant, it is readily detectable in his
plasma (n = 22) and serum (n = 12) samples and was consistent for over a year.
Log2-transformed abundance differences were tabulated (Dataset S4) and plotted
as scatterplots (Fig. 3) against log2-transformedmean abundance values (MA plots)
and only considered significant for Padj < 0.05 using ggplot2 (48) (ggplot2.org).
Boxplots were generated using the ReportingTools package (49).
Calculation of correlation coefficients. Pearson product moment correlation
coefficients were calculated for sample pairs using Corrplot, and pairwise
comparisons were performed for groups of technical replicates as well as
groups of all independent samples. Sample classes were taken into consid-
eration where specified. To describe overall correlations within the groups,
their medians and first and third quartile values are reported.
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